- Home
- HP vs DYN Comparison
HP vs DYN Comparison
Compare HP & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HP
- DYN
- Stock Information
- Founded
- HP 1920
- DYN 1984
- Country
- HP United States
- DYN United States
- Employees
- HP N/A
- DYN N/A
- Industry
- HP Oil & Gas Production
- DYN Medicinal Chemicals and Botanical Products
- Sector
- HP Energy
- DYN Health Care
- Exchange
- HP Nasdaq
- DYN Nasdaq
- Market Cap
- HP 3.6B
- DYN 3.4B
- IPO Year
- HP N/A
- DYN 2020
- Fundamental
- Price
- HP $34.89
- DYN $29.92
- Analyst Decision
- HP Hold
- DYN Strong Buy
- Analyst Count
- HP 9
- DYN 9
- Target Price
- HP $38.57
- DYN $52.44
- AVG Volume (30 Days)
- HP 1.4M
- DYN 1.1M
- Earning Date
- HP 11-13-2024
- DYN 11-12-2024
- Dividend Yield
- HP 0.75%
- DYN N/A
- EPS Growth
- HP N/A
- DYN N/A
- EPS
- HP 3.43
- DYN N/A
- Revenue
- HP $2,756,607,000.00
- DYN N/A
- Revenue This Year
- HP $22.65
- DYN N/A
- Revenue Next Year
- HP $12.27
- DYN N/A
- P/E Ratio
- HP $9.70
- DYN N/A
- Revenue Growth
- HP N/A
- DYN N/A
- 52 Week Low
- HP $29.46
- DYN $10.12
- 52 Week High
- HP $44.11
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- HP 46.44
- DYN 45.37
- Support Level
- HP $32.99
- DYN $27.04
- Resistance Level
- HP $34.14
- DYN $35.68
- Average True Range (ATR)
- HP 1.25
- DYN 2.27
- MACD
- HP -0.26
- DYN 0.20
- Stochastic Oscillator
- HP 18.57
- DYN 26.74
About HP Helmerich & Payne Inc.
Helmerich & Payne maintains one of the largest fleets of land drilling rigs in the US. The company's FlexRig line is the leading choice to drill horizontal wells for production of US tight oil and gas. H&P is present in nearly every major US shale play and has a small but growing presence internationally.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.